Findings
========

Background
----------

Renal cell carcinoma (RCC) consists of various tumor types \[[@B1]\]; clear cell RCC (ccRCC) accounts for approximately 70-80 % of the RCCs, papillary RCC (pRCC) for 10-15 % of cases, chromophobe RCC (chRCC) for approximately 5 %, and collecting duct carcinoma for less than 1 % of RCCs. Approximately 4-5 % of RCCs do not fit the histopathological criteria and are referred to as unclassified carcinomas \[[@B1]\]. The RCC types represent tumor groups with different genetic and molecular properties, as reviewed in \[[@B2]\] and \[[@B3]\]. When RCC types are analyzed collectively, the results predominantly reflect the properties of ccRCC, since this type accounts for the majority of RCC cases. Previous studies have revealed altered expression of epidermal growth factor (EGF) receptor (EGFR)-family members and their endogenous inhibitor leucine-rich and immunoglobulin-like domains 1 (LRIG1) in renal cell carcinoma (RCC). The EGFR family consists of four receptor tyrosine kinases, EGFR (ERBB1, HER1), ERBB2 (HER2, neu), ERBB3 (HER3), and ERBB4 (HER4) \[[@B4]\], of which down-stream intracellular signaling pathways regulate cell proliferation, differentiation, and migration \[[@B5]\]. LRIG1 \[[@B6]\] negatively regulates all four members of the EGFR-family \[[@B7]-[@B10]\]. LRIG1 is also a negative regulator of the MET - and RET -receptor tyrosine kinases \[[@B11],[@B12]\]. LRIG1 is down-regulated in several cancers and cancer cell lines, including breast cancer and squamous cell carcinoma of the skin and uterine cervix, where low LRIG1 expression correlates with poor patient survival \[[@B13]-[@B17]\].

Previously, we reported the expression of the EGFR-family members and LRIG1 in a limited number of RCC-patients \[[@B18],[@B19]\]. Here, we extended these studies to a larger patient cohort, and analyzed the RCC types individually.

Methods
=======

In this study we analyzed tumor samples from 104 patients who underwent nephrectomy at the Department of Urology, Umeå University Hospital, between the years 1986 and 1999 (Table [1](#T1){ref-type="table"}). These tumors included 81 ccRCC, 15 pRCC, 7 chRCC, and 1 unclassified carcinoma. Additionally, specimens of histologically verified non-neoplastic kidney cortex were obtained from 27 of the nephrectomized kidneys. RNA was prepared and quantitative real-time reverse transcription- (RT-) PCR of *EGFRERBB2, ERBB3, ERBB4LRIG1,* and RN18S1 (18 S rRNA) was performed as previously described \[[@B18],[@B19]\]. To correct for differences in RNA quality and quantity, apparent levels of RN18S1 were used to normalize the *EGFRERBB2-4,* and *LRIG1* values in each respective RNA sample. To test the reliability of the analysis, all five protein encoding genes were analyzed five times for three different samples. The maximum coefficient of variation and the standard deviation, expressed as a percentage of the mean, was 22 %. Patients provided informed consent for the use of both their tumor material and clinical data for studies. This study was approved by the research ethics committee at Umeå University Medical Faculty (No 02--340).

###### 

Characteristics of the patients and tumors included in the study

  **Total no. of patients**                         **104**          
  ------------------------------------------------- ---------------- --------------
  Sex                                               male/female      56/48
  Age in years                                      median (range)   65 (25--85)
  Tumor diameter in mm                              median (range)   80 (30--250)
  Survival in months                                Range            0-130
  Tumor stage (WHO)                                 I                26
  (As derived from TNM)                             II               15
                                                    III              30
                                                    IV               33
  Tumor grade (Fuhrman)                             1                4
                                                    2                14
                                                    3                60
                                                    4                26
  RCC type by histology                             Clear cell       81
                                                    Papillary        15
                                                    Chromophobe      7
                                                    Unclassified     1
  Patients with known metastasis at diagnosis       35               
  Patients who died from the disease                57               
  Patients dead from other causes                   16               
  Patients alive at last follow-up (with disease)   31 (3)           

Statistical analysis was performed using nonparametric statistics, as normal distribution of the data could not be assumed. For comparisons between two groups, the Mann--Whitney U-test was used. Comparisons of more than two groups were performed using the Kruskal-Wallis test. Comparisons between coupled samples were performed using the Wilcoxon signed-rank test. Correlations were analyzed according to Spearman's rank correlation. Survival analysis was performed by first comparing patients with mRNA expression levels either above or below the median and then subjecting the data to Kaplan-Meier analysis by log-rank test. All P-values were two-sided. All calculations were performed using SPSS 14.0 software.

Results
=======

The expression of *EGFR* was higher in all RCC types combined compared to kidney cortex tissue (P \< 0.001) (Table [2](#T2){ref-type="table"}). This up-regulation was significant for both ccRCC (P \< 0.001) and pRCC (P = 0.016), but not for chRCC (P = 0.257) (Figure [1](#F1){ref-type="fig"}A; Table [2](#T2){ref-type="table"}). This is in line with earlier findings by us and others \[[@B18],[@B20]-[@B24]\].

###### 

Significant differences in mRNA expression between kidney cortex and the RCC types

          **All RCC combined\***   **ccRCC\***   **pRCC\***   **chRCC\***   **Altered expression**   **Difference RCC types†**
  ------- ------------------------ ------------- ------------ ------------- ------------------------ ---------------------------
  EGFR    \< 0.001                 0.001         0.016        NS            Up-regulation            NS
  ErbB2   0.003                    0.001         NS           NS            Down-regulation          \< 0.001
  ErbB3   NS                       NS            NS           NS            \-                       NS
  ErbB4   0.001                    \< 0.001      0.001        0.03          Down-regulation          NS
  LRIG1   NS                       0.015         NS           NS            Down-regulation          0.002

\* P-values were calculated in comparison to kidney cortex using the Mann--Whitney U-test.

† Comparison of the significant differences between the RCC types was performed using the Kruskal-Wallis test.

NS, non-significant.

![**Boxplots of the relative mRNA expression of the*EGFR*-family members and*LRIG1*in both the kidney cortex and the RCC types.** Relative mRNA expression of *EGFR*, *ERBB2, ERRB3, ERRB4,* and *LRIG1* was quantified in kidney cortex (n = 27), ccRCC (n = 81), pRCC (n = 15), and chRCC (n = 7). (A) *EGFR* mRNA expression was elevated in ccRCC and pRCC compared to kidney cortex. (Increased expression in chRCC was not significant, but expression levels were similar to other RCC groups.) (B) *ERBB2* mRNA expression was significantly lower in ccRCC compared to kidney cortex. In pRCC and chRCC, expression did not significantly differ from kidney cortex. (C) *ERBB3* mRNA expression was not significantly different between any of the RCC types compared to the kidney cortex. (D) *ERBB4* mRNA expression was significantly reduced in all RCC types compared to kidney cortex. (E) *LRIG1* mRNA expression was significantly lower in ccRCC compared to kidney cortex. In pRCC and chRCC, LRIG1 expression did not significantly differ from kidney cortex. Outlier values are marked °. Significant differences compared to expression in the kidney cortex are labeled (\*) for P \< 0.05 and (\*\*) for P \< 0.01.](1756-0500-5-216-1){#F1}

*ERBB2* expression was significantly reduced in all RCC types combined compared to kidney cortex (P = 0.003); however, reduced expression was only significant in ccRCC (P = 0.001) and not in pRCC or chRCC (Figure [1](#F1){ref-type="fig"}B). These results indicate that the previously described down-regulation of *ERBB2* in RCC \[[@B19]\] is actually a result of down-regulation in the ccRCCs.

*ERBB3* expression was similar in RCC and non-neoplastic kidney cortex, and there was no significant expression difference between RCC types (Figure [1](#F1){ref-type="fig"}C).

*ERBB4* expression was markedly lower in all the different RCC types than in kidney cortex (P \< 0.001). There was no difference in *ERBB4* expression between the RCC types (Figure [1](#F1){ref-type="fig"}D). Thus, the earlier described down-regulation of *ERBB4* in RCC \[[@B19]\] was here shown to be prominent in all RCC types analyzed. In fact, no *ERBB4* expression could be detected in 51 out of the 104 tumors analyzed. This pronounced down-regulation of *ERBB4* may suggest an important role for this receptor tyrosine kinase in inhibiting the development of RCC.

The expression *of LRIG1* was reduced in ccRCC compared to kidney cortex (P = 0.020). The expression of *LRIG1* in pRCC and chRCC was not significantly different from that of kidney cortex (Figure [1](#F1){ref-type="fig"}E). Thus, the previously described down-regulation of LRIG1 in RCC \[[@B18]\] was restricted to ccRCC. This finding could indicate a tumor suppressive role for LRIG1 in the context of ccRCC that is not present or of reduced importance in other types of RCC.

The expression levels of *EGFRERBB2-4,* and *LRIG1* correlated significantly with each other in most cases (Table [3](#T3){ref-type="table"}). This was possibly due to LRIG1 expression being up-regulated by receptor activation \[[@B7]\] or due to metholodical issues, e.g. due to variation in the expression of the reference gene, RN18S1. There was a non-significant trend to an inverse correlation (R = −0.166 P = 0.058) between the expression levels of *EGFR* and *ERBB4*. This results is in line with *EGFR* being up-regulated and *ERBB4* being down-regulated in tumors.

###### 

Correlation of mRNA expression levels between the analyzed genes

                    **EGFR**   **ErbB2**   **ErbB3**   **ErbB4**   **LRIG1**
  ------- --------- ---------- ----------- ----------- ----------- -----------
  EGFR    CC        1.000      0.274\*     0.425\*     −0.166      0,370\*
          P-value   \-         0.002       \<0.001     0.058       \<0.001
  ErbB2   CC        0.274\*    1.000       0.586\*     0.375\*     0.456\*
          P-value   0.002      \-          \<0.001     \<0.001     \<0.001
  ErbB3   CC        0.425\*    0.586\*     1.000       0.152       0.456
          P-value   \<0.001    \<0.001     \-          0.082       0.000
  ErbB4   CC        −0.166     0.375\*     0.152       1.000       0.277\*
          P-value   0.058      \<0.001     0.082       \-          0.001
  LRIG1   CC        0.370\*    0.456       0.456       0.277\*     1.000
          P-value   \<0.001    \<0.001     \<0.001     0.001       \-

CC, Correlation coefficient according to Spearman.

\*Significant with P-value \<0.05.

The expression levels of *ERBB3* within ccRCC were inversely correlated with tumor grade and tumor size (R = −0.287, P = 0.009 and R = −0.244, P = 0.027, respectively). As expression of *ERBB3* mRNA was low and did not differ between tumors and kidney cortex or between RCC types, the biological significance of this finding is highly uncertain. No other significant correlation was observed between the expression of *EGFR*-family members or *LRIG1* and the size, grade, or stage of the tumors. Survival analysis comparing patients with tumors expressing above or below median mRNA values of the five genes revealed no significant difference in overall survival or cancer specific survival, neither in ccRCC patients or all RCC patients combined ( Additional file [1](#S1){ref-type="supplementary-material"} Figure S1). The patient groups for the other RCC types were too small for meaningful survival analyses. The previously described and non-significant association between LRIG1 expression and tumor grade and patient survival \[[@B18]\] was not confirmed in the present and larger study. Therefore, it appears that although LRIG1 may possess a tumor suppressive function in ccRCC, it does not appear to be an important prognostic factor in RCC.

Conclusions
===========

This study demonstrated that the expression of *EGFR*, *ERBB3* and *ERBB4* was similar throughout different RCC types, whereas the expression of *ERBB2* and *LRIG1* differed between the various types of RCC. This demonstrates potentially important differences and similarities in the expression of the EGFR-family members and LRIG1 genes between different RCC types. Up-regulated gene expression of *EGFR* compared to kidney cortex was found in all RCC types analyzed. A strong down-regulation of *ERBB4* was observed in all RCC types analyzed, while down-regulation of *ERBB2* and *LRIG1* was found only in ccRCC. The biological and clinical significance of these differences in gene expression warrants further study.
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**Figure S1**Kaplan-Meier survival curves of cancer specific survival comparing patients with tumors above and below median expression of all five genes.
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